---
title: "Pharmacometric Modeling Strategies"
---

:::{.callout-caution}
# Under construction
:::

## Alternatives in PKPD modelling

* Assume a PK model
  * Estimate PK and PD parameters in a simultaneous fit (SIM)
  * Estimate PK parameters first and then fit PD
    * Condition on individual PK parameter estimates
      * Assume no error in parameters (IPP = Individual PK Parameters)
      * Account for error in parameters (IPPSE = Individual PK Parameters Standard Error)*
    * Fix population PK parameters
      * Include individual PK data (PPP&D = Population PK Parameters & Data)**
      * Don’t include individual PK data (PPP = Population PK Parameters)

*LaCroix et al., JPKPD 39:177–193, 2012  
**Wade and Karlsson, PAGE 1999  
Abbreviations in Zhang et al 2003  

## Important considerations

### Impact of a model

* What is the modeling used for? (e.g., bridging, dose, SmPC^[Summary of Product Characteristics] parameters?)
  * Does the conclusion align with the aim?
* What data is available?
  * Rich data
  * Sparse data
* What is the structural model?
  * Reasonable parameter estimates and RSE^[Relative standard error]'s?
  * Graphical evaluation (VPC^[Visual Predictive Check] first)
  * Covariate evaluation

* Exposure-response is generally non-informative if only one dose-level is given, even if weight-adjusted

### Reviewing models
* Does my conclusion align with the authors?
* Questions NGN (eNGiNe)
  * Need-to-know: Will affect conclusion (Major objection)
  * Good-to-know: Could affect conclusion (Other concern)
  * Nice-to-know: Won't affect conclusion (avoid asking this question)

## References

* Musuamba et al., 2021, https://doi.org/10.1002/psp4.12669
* Skottheim Rusten & Musuamba, 2021, https://doi.org/10.1002/psp4.12708
